IL287536B2 - Compositions and methods for using cannabinoids for neuroprotection - Google Patents
Compositions and methods for using cannabinoids for neuroprotectionInfo
- Publication number
- IL287536B2 IL287536B2 IL287536A IL28753621A IL287536B2 IL 287536 B2 IL287536 B2 IL 287536B2 IL 287536 A IL287536 A IL 287536A IL 28753621 A IL28753621 A IL 28753621A IL 287536 B2 IL287536 B2 IL 287536B2
- Authority
- IL
- Israel
- Prior art keywords
- composition
- neuroprotective
- neuroprotective compound
- compound
- cannabinol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838216P | 2019-04-24 | 2019-04-24 | |
| PCT/CA2020/050547 WO2020215164A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for use of cannabinoids for neuroprotection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL287536A IL287536A (en) | 2021-12-01 |
| IL287536B1 IL287536B1 (en) | 2025-11-01 |
| IL287536B2 true IL287536B2 (en) | 2026-03-01 |
Family
ID=72940570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287536A IL287536B2 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for using cannabinoids for neuroprotection |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230043428A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3958856A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7633179B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220080045A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114007603A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020261515B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134764A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287536B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021012960A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202111809XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020215164A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115006404A (zh) * | 2022-08-09 | 2022-09-06 | 昆药集团股份有限公司 | 一种具有视神经保护功效的药物组合物及其应用 |
| US20240139272A1 (en) * | 2022-10-27 | 2024-05-02 | Kemin Industries, Inc. | Use of a spearmint extract for retina neurotrophism |
| AU2024206205A1 (en) * | 2023-01-04 | 2025-07-17 | Florascience Inc. | Cannabinoids for use in the treatment of a neurodegenerative disease or condition |
| IL327899A (en) * | 2023-10-23 | 2026-06-01 | Inmed Pharmaceuticals Inc | Compositions and methods for use of cannabinol compounds in neuroprotection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018205022A1 (en) * | 2017-05-08 | 2018-11-15 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| BR112013012468A2 (pt) * | 2010-11-18 | 2016-09-06 | Pier Pharmaceuticals | método de tratar um indivíduo com um distúrbio sensível a canabinóide, de estabelecer uma dose ideal, de tratar um indivíduo com um distúrbio de apneia do sono, e, kit |
| MX2017005277A (es) * | 2014-10-21 | 2018-01-11 | United Cannabis Corp | Extractos de cannabis y métodos de preparación y uso de la misma. |
| MA41299A (fr) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
| US20170266153A1 (en) * | 2015-02-27 | 2017-09-21 | Ebbu, LLC | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| EP3261629A4 (en) * | 2015-02-27 | 2018-12-05 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| US20160282371A1 (en) * | 2015-03-28 | 2016-09-29 | Quantalytical Labs Inc. | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits |
| IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
| JP7225103B2 (ja) * | 2016-10-11 | 2023-02-20 | ジービーエス グローバル バイオファーマ,インコーポレイテッド | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
| WO2018118197A1 (en) * | 2016-12-21 | 2018-06-28 | Richard Postrel | Healthier aging in domesticated animals |
| WO2018205038A1 (en) * | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
| US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
-
2020
- 2020-04-24 CA CA3134764A patent/CA3134764A1/en active Pending
- 2020-04-24 JP JP2021563360A patent/JP7633179B2/ja active Active
- 2020-04-24 KR KR1020217036628A patent/KR20220080045A/ko not_active Withdrawn
- 2020-04-24 WO PCT/CA2020/050547 patent/WO2020215164A1/en not_active Ceased
- 2020-04-24 CN CN202080046190.4A patent/CN114007603A/zh active Pending
- 2020-04-24 IL IL287536A patent/IL287536B2/en unknown
- 2020-04-24 AU AU2020261515A patent/AU2020261515B2/en active Active
- 2020-04-24 EP EP20794650.0A patent/EP3958856A4/en active Pending
- 2020-04-24 SG SG11202111809XA patent/SG11202111809XA/en unknown
- 2020-04-24 MX MX2021012960A patent/MX2021012960A/es unknown
- 2020-04-24 US US17/606,003 patent/US20230043428A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018205022A1 (en) * | 2017-05-08 | 2018-11-15 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
Non-Patent Citations (1)
| Title |
|---|
| KABIRI MARYAM ET AL:, A STIMULUS-RESPONSIVE, IN SITU-FORMING, NANOPARTICLE-LADENHYDROGEL FOR OCULAR DRUG DELIVERY, 5 March 2018 (2018-03-05) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7633179B2 (ja) | 2025-02-19 |
| AU2020261515B2 (en) | 2025-10-23 |
| EP3958856A1 (en) | 2022-03-02 |
| SG11202111809XA (en) | 2021-11-29 |
| CA3134764A1 (en) | 2020-10-29 |
| US20230043428A1 (en) | 2023-02-09 |
| KR20220080045A (ko) | 2022-06-14 |
| IL287536A (en) | 2021-12-01 |
| EP3958856A4 (en) | 2023-01-25 |
| WO2020215164A1 (en) | 2020-10-29 |
| MX2021012960A (es) | 2022-01-04 |
| AU2020261515A1 (en) | 2021-11-18 |
| CN114007603A (zh) | 2022-02-01 |
| IL287536B1 (en) | 2025-11-01 |
| JP2022530471A (ja) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2597163B (en) | Cannabinoid compositions and methods of using | |
| IL276135A (en) | Preparations and methods of use | |
| SG11202111809XA (en) | Compositions and methods for use of cannabinoids for neuroprotection | |
| GB202105087D0 (en) | Microbial compositions and methods of use | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL269590A (en) | Methods and compositions for reducing immunogenicity | |
| IL275739A (en) | Preparations for cryopreservation and methods of their use | |
| IL282533A (en) | Oligosaccharide preparations and methods of using them | |
| GB2597170B (en) | Diluents for compositions of cannabinoids and uses thereof | |
| EP3606493A4 (en) | DENTAL CEMENT COMPOSITIONS AND METHODS OF USE | |
| IL287797A (en) | Oligosaccharide preparations and methods of use | |
| SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| IL283950A (en) | Methods and compositions for creating cannabinoids | |
| EP3285755A4 (en) | Compositions and methods for neuroprotection and treatment of neurodegeneration | |
| IL276680A (en) | Silica fiber preparations and methods of use | |
| IL285367A (en) | Methods and compounds for inhibiting the expression of cyp27a1 | |
| EP4054514A4 (en) | COMPOSITIONS CONTAINING FENCHOLES AND METHOD OF USE | |
| EP3843721A4 (en) | OPHTHALMIC COMPOSITIONS AND METHODS OF USE | |
| IL291538A (en) | Anti-aging preparations and methods of using them | |
| HK40065278A (en) | Nanotransposon compositions and methods of use | |
| HK40065159A (en) | Sirt1-sarna compositions and methods of use | |
| HK40049684A (en) | Bismuth-thiol compositions and methods of use | |
| AU2019903896A0 (en) | Compositions and methods of use | |
| HK40042765A (en) | Sirt1-sarna compositions and methods of use |